The presence of anti-citrullinated protein antibodies (ACPA) does not affect the clinical response to adalimumab in a group of RA patients with the tumor necrosis factor (TNF) α-308 G/G promoter polymorphism

Clinical Rheumatology

Volumn 30, Issue 3, 2011, Pages 391-395

  Soto, Lilian ^a   Sabugo, Francisca ^a   Catalan, Diego ^b   Wurmann, Pamela ^a   Cermenatti, Tomás ^a   Gatica, Héctor ^a   Aravena, Octavio ^b   Salazar, Lorena ^b   Aguillón, Juan Carlos ^b   Cuchacovich, Miguel ^a  

^a HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^b UNIVERSITY OF CHILE   (Chile)

Author keywords

Adalimumab; Anti TNF; Rheumatoid arthritis; TNF polymorphism

Indexed keywords

ADALIMUMAB; CITRULLINATED PROTEIN ANTIBODY; IMMUNOGLOBULIN M; LEFLUNOMIDE; METHOTREXATE; PROTEIN ANTIBODY; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL PRACTICE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES, CYCLIC; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79954625104     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-011-1679-4     Document Type: Article

References (19)

1. D van der Woude TW Huizinga 2008 Translating basic research into clinical rheumatology Best Pract Res Clin Rheumatol 22 299 310 18455686 10.1016/j.berh.2008.01.009 (Pubitemid 351606946)
2. L Senolt J Vencovsky K Pavelka C Ospelt S Gay 2009 Prospective new biological therapies for rheumatoid arthritis Autoimmun Rev 9 102 107 19328245 10.1016/j.autrev.2009.03.010 1:CAS:528:DC%2BD1MXhs1SjtL7M
3. YH Lee JD Ji SC Bae GG Song 2010 Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update Rheumatol 37 740 746 10.3899/jrheum.090707 1:CAS:528:DC%2BC3cXmtFCru7w%3D
4. H Marotte P Miossec 2010 Biomarkers for prediction of TNFalpha blockers response in rheumatoid arthritis Joint Bone Spine 77 297 305 20478724 10.1016/j.jbspin.2010.02.026 1:CAS:528:DC%2BC3cXpsVGis7c%3D
5. M Cuchacovich L Soto M Edwardes M Gutierrez C Llanos D Pacheco, et al. 2006 Tumor necrosis factor-α -308 G/G promoter polymorphism and TNF-α levels correlate with a better response to adalimumab in patients with rheumatoid arthritis Scand J Rheumatol 35 435 440 17343250 10.1080/03009740600904284 1:CAS:528:DC%2BD2sXhvFKnsL0%3D (Pubitemid 47215721)
6. B Mugnier N Balandraud A Darque C Roudier J Roudier D Reviron 2003 Polymorphism at position -308 of the tumor necrosis factor gene influences outcome of infliximab therapy in rheumatoid arthritis Arthritis Rheum 48 1849 1852 12847678 10.1002/art.11168 1:CAS:528:DC%2BD3sXmtFart7c%3D (Pubitemid 36828679)
7. PK Gregersen J Silver RJ Winchester 1987 The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis Arthritis Rheum 30 1205 1213 2446635 10.1002/art.1780301102 1:CAS:528:DyaL1cXhtVOisbY%3D (Pubitemid 18005792)
8. The MHC sequencing consortium 1999 Complete sequence and gene map of a human major histocompatibility complex Nature 401 921 923 10.1038/44853 (Pubitemid 29518961)
9. AH van der Helm-van Mil KN Verpoort FC Breedveld TW Huizinga RE Toes RR de Vries 2006 The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis Arthritis Rheum 54 1117 1121 16572446 10.1002/art.21739 (Pubitemid 43672924)
10. JK de Vries-Bouwstra YP Goekoop-Ruiterman KN Verpoort GM Schreuder JA Ewals JP Terwiel, et al. 2008 Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antigens in relation to different treatment strategies Arthritis Rheum 58 1293 1298 18438829 10.1002/art.23439 (Pubitemid 351705918)
11. M Cuchacovich D Catalan E Wainstein H Gatica L Soto O Aravena, et al. 2008 Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis Clin Exp Rheumatol 26 1067 1073 19210871 1:STN:280:DC%2BD1M7jsFCrsQ%3D%3D
12. C Alessandri M Bombardieri N Papa M Cinquini L Magrini A Tincani, et al. 2004 Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF alpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement Ann Rheum Dis 63 1218 1221 15361374 10.1136/ard.2003.014647 1:CAS:528:DC%2BD2cXovFOmsrg%3D (Pubitemid 39273496)
13. F Atzeni P Sarzi-Puttini D Dell' Acqua S de Portu G Cecchini C Cruini, et al. 2006 Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study Arthritis Res Ther 8 R3 16356192 10.1186/ar1851
14. HA Chen KC Lin CH Chen HT Liao HP Wang HN Chang, et al. 2006 The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis Ann Rheum Dis 65 35 39 15975966 10.1136/ard.2005.038851 1:CAS:528:DC%2BD28Xnt12htA%3D%3D (Pubitemid 41815636)
15. J Vinasco Y Beraún A Nieto A Fraile L Mataran E Pareja, et al. 1997 Polymorphism at the TNF loci in rheumatoid arthritis Tissue Antigens 49 74 78 9027971 10.1111/j.1399-0039.1997.tb02715.x 1:CAS:528:DyaK2sXpt1Chtw%3D%3D
16. F Bobbio-Pallavicini R Caporali C Alpini S Avalle O Epis C Klersy, et al. 2007 High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor a inhibitors in rheumatoid arthritis Ann Rheum Dis 66 302 307 17079248 10.1136/ard.2006.060608 1:CAS:528: DC%2BD2sXjvFShsbs%3D (Pubitemid 46579628)
17. Y Braun-Moscovici D Markovits O Zinder D Schapira A Rozin M Ehrenburg, et al. 2006 Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-a therapy in patients with rheumatoid arthritis J Rheumatol 33 497 500 16511906 1:CAS:528:DC%2BD28XivVGhtr4%3D (Pubitemid 43334571)
18. KL Hyrich KD Watson AJ Silman DP Symmons 2006 Predictors of response to anti-TNF-a therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register Rheumatology (Oxford) 45 1558 1565 10.1093/rheumatology/kel149 1:CAS:528:DC%2BD28Xht1Kns73E (Pubitemid 44817065)
19. C Potter KL Hyrich A Tracey M Lunt D Plant DP Symmons, et al. 2009 Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis Ann Rheum Dis 68 69 74 18375541 10.1136/ard.2007.084715 1:CAS:528: DC%2BD1MXhslOlt70%3D